Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease

NCT07647614 is registered in ClinicalTrials.gov with Energenesis Biomedical Co., Ltd. as lead sponsor.

NCT NCT07647614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease
Lead sponsor
Energenesis Biomedical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
January 1, 2030
Enrollment
105 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)